Celecoxib/hydrochlorothiazide - Adhera Therapeutics
Latest Information Update: 28 Oct 2021
At a glance
- Originator Marina Biotech
- Developer Adhera Therapeutics
- Class Anti-inflammatories; Antihypertensives; Antineoplastics; Thiazides
- Mechanism of Action Cyclo-oxygenase 2 inhibitors; Diuretics
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Cancer in USA
- 08 Sep 2017 Preclinical trials in Cancer in USA (unspecified route) prior to 08/09/2017
- 08 Sep 2017 Pharmacodynamics data from a preclinical trial in Cancer presented at the 42nd European Society for Medical Oncology (ESMO-2017)